187 related articles for article (PubMed ID: 36005189)
21. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
22. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
23. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
24. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.
Meri-Abad M; Moreno-Manuel A; García SG; Calabuig-Fariñas S; Pérez RS; Herrero CC; Jantus-Lewintre E
Crit Rev Oncol Hematol; 2023 Feb; 182():103891. PubMed ID: 36565893
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
27. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
28. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
29. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Song P; Cui X; Bai L; Zhou X; Zhu X; Zhang J; Jin F; Zhao J; Zhou C; Zhou Y; Zhang X; Wang K; Wang Q; Yu Y; Zhang X; Bai C; Zhang L
Thorac Cancer; 2019 May; 10(5):1303-1309. PubMed ID: 31016875
[TBL] [Abstract][Full Text] [Related]
31. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
[TBL] [Abstract][Full Text] [Related]
32. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
;
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
[TBL] [Abstract][Full Text] [Related]
33. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
[TBL] [Abstract][Full Text] [Related]
34. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
35. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
36. Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report.
Miao Q; Zhang L; Zheng X; Jiang K; Wu B; Lin G
Ann Palliat Med; 2021 Apr; 10(4):4982-4986. PubMed ID: 33966433
[TBL] [Abstract][Full Text] [Related]
37. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
38. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
40. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]